New York State Teachers Retirement System increased its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) by 1.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 80,531 shares of the biotechnology company’s stock after purchasing an additional 1,393 shares during the period. New York State Teachers Retirement System owned approximately 0.11% of Axon Enterprise worth $18,107,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in the stock. American Century Companies Inc. raised its holdings in shares of Axon Enterprise by 103.8% in the 1st quarter. American Century Companies Inc. now owns 6,194 shares of the biotechnology company’s stock valued at $853,000 after purchasing an additional 3,155 shares in the last quarter. Private Advisor Group LLC increased its stake in shares of Axon Enterprise by 40.3% in the first quarter. Private Advisor Group LLC now owns 3,458 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 994 shares during the period. Great West Life Assurance Co. Can increased its stake in shares of Axon Enterprise by 12.3% in the first quarter. Great West Life Assurance Co. Can now owns 37,062 shares of the biotechnology company’s stock worth $5,247,000 after acquiring an additional 4,048 shares during the period. Raymond James Trust N.A. increased its stake in shares of Axon Enterprise by 4.7% in the first quarter. Raymond James Trust N.A. now owns 3,753 shares of the biotechnology company’s stock worth $517,000 after acquiring an additional 168 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Axon Enterprise by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 236,287 shares of the biotechnology company’s stock worth $32,545,000 after acquiring an additional 4,897 shares during the period. 76.47% of the stock is owned by hedge funds and other institutional investors.
Axon Enterprise Stock Performance
NASDAQ:AXON opened at $196.16 on Tuesday. The company’s 50-day moving average price is $195.53 and its 200-day moving average price is $203.73. The company has a current ratio of 3.33, a quick ratio of 2.97 and a debt-to-equity ratio of 0.48. The company has a market cap of $14.49 billion, a P/E ratio of 103.79 and a beta of 0.90. Axon Enterprise, Inc. has a twelve month low of $94.86 and a twelve month high of $229.95.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.48. The firm had revenue of $343.04 million for the quarter, compared to the consensus estimate of $312.07 million. Axon Enterprise had a net margin of 10.76% and a return on equity of 10.65%. On average, sell-side analysts forecast that Axon Enterprise, Inc. will post 1.58 earnings per share for the current fiscal year.
Insider Activity
In other news, Director Julie A. Cullivan sold 2,013 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $197.58, for a total value of $397,728.54. Following the sale, the director now directly owns 7,062 shares of the company’s stock, valued at approximately $1,395,309.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Axon Enterprise news, Director Julie A. Cullivan sold 2,013 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $197.58, for a total transaction of $397,728.54. Following the completion of the transaction, the director now owns 7,062 shares in the company, valued at approximately $1,395,309.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Julie A. Cullivan sold 1,180 shares of the business’s stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $196.00, for a total transaction of $231,280.00. Following the sale, the director now owns 5,882 shares of the company’s stock, valued at approximately $1,152,872. The disclosure for this sale can be found here. In the last three months, insiders have purchased 45,250 shares of company stock valued at $8,735,200 and have sold 54,458 shares valued at $10,534,340. Insiders own 6.10% of the company’s stock.
Analyst Ratings Changes
Several analysts recently commented on the stock. JMP Securities restated a “market outperform” rating and set a $235.00 price target on shares of Axon Enterprise in a research report on Friday, April 14th. Barclays raised their price target on shares of Axon Enterprise from $222.00 to $256.00 in a research report on Wednesday, May 10th. TheStreet lowered shares of Axon Enterprise from a “b-” rating to a “c+” rating in a research report on Friday, May 26th. Needham & Company LLC restated a “buy” rating and set a $240.00 price target on shares of Axon Enterprise in a research report on Thursday, April 13th. Finally, StockNews.com initiated coverage on shares of Axon Enterprise in a research report on Thursday, May 18th. They issued a “hold” rating on the stock. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $232.64.
Axon Enterprise Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Axon Enterprise, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Axon Enterprise wasn’t on the list.
While Axon Enterprise currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
